Vertex Gears Up For Major Milestones, Starting With Sickle Cell Launch And Pain Drug Readout
Executive Summary
Having long attracted investors thanks to its promising pipeline, the moment of truth approaches for Vertex’s sickle cell gene therapy exo-cel, and VX-548, which has potential to transform acute and chronic pain treatment.